Cellcolabs
Cellcolabs is a Swedish biotech producing GMP-certified mesenchymal stem cells (MSCs) at industrial scale, supplying university hospitals, research institutions, biotech companies, and clinics globally while operating clinical subsidiaries in the Bahamas, UAE, and Southeast Asia.
- Company typePrivate
- Founded2021
- HeadquartersSolna, Sweden
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cellcolabs does
Cellcolabs is a Swedish biotech founded in 2021 that produces GMP-certified mesenchymal stem cells (MSCs) at industrial scale for both research supply and clinical therapeutic use. Manufacturing is conducted at a GMP-certified facility in Stockholm under oversight of the Swedish Medical Products Agency (Läkemedelsverket), with the underlying production protocol developed over 25+ years at Karolinska Institutet by Professor Katarina Le Blanc. A single bone marrow donation is reported to yield up to 200 therapeutic doses, and the company has publicly targeted a 90% reduction in MSC production cost by 2035 through scaled manufacturing.
The company serves four primary customer segments: university hospitals, academic and translational research institutions, biotech and pharmaceutical companies, and clinics offering MSC-based treatments. It operates dedicated regional vehicles — Cellcolabs Asia (Bangkok) for Southeast Asia commercialization and Cellcolabs Clinical (Bahamas/UAE) — which provide direct-to-clinic and DTC channels in jurisdictions where cell-therapy patient flows are accessible. The revenue model combines product sales of MSC batches to research customers, sponsorship of clinical trials at named academic medical centers (e.g., Rigshospitalet, InnoHK CNRM, Burjeel Medical City), and clinical treatments delivered through partner clinics.
Strategic positioning has shifted materially in 2025–2026: a $12M funding round closed in October 2025 to support international expansion, a new CEO with senior biotech/big-pharma pedigree (Vincent Metzler) was appointed in June 2026, and the company underwent a restructuring to prioritize B2B commercialization and orthopedic indications — notably knee osteoarthritis — alongside ongoing work in Sjögren's Syndrome and musculoskeletal regeneration.
Cellcolabs firmographics
Firmographics- Name
- Cellcolabs
- Legal name
- Cellcolabs AB
- Website
- https://cellcolabs.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cellcolabs is a Swedish biotech producing GMP-certified mesenchymal stem cells (MSCs) at industrial scale, supplying university hospitals, research institutions, biotech companies, and clinics globally while operating clinical subsidiaries in the Bahamas, UAE, and Southeast Asia.
- Ownership category
- akta.pro rank
Cellcolabs industry classification
Industry- Product category
- Cell Therapy Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD)
Keywords
Where Cellcolabs is headquartered
LocationHeadquarters
- HQ city
- Solna
- HQ country
- Sweden
- HQ region
- Europe
Offices4 records
Markets served
Cellcolabs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Stem Cell Product Sales: Sale of GMP-certified mesenchymal stem cells to university hospitals, research institutions, biotechnology companies, and clinics globally. The company sells both bone-marrow-derived MSCs and adipose-derived MSCs for clinical research and therapeutic applications.
- Clinical Trial Sponsorship: Sponsorship of clinical trials through Cellcolabs Clinical subsidiary, assessing MSC therapies for conditions including cardiovascular disease, musculoskeletal injuries, Sjögren's Syndrome, and knee osteoarthritis. Trials conducted in the Bahamas, UAE, and Denmark.
- Clinical Products and Services: Revenue from commercial clinical treatments through Cellcolabs Clinical, with 2025 revenues increasing approximately 40% to around 57 MSEK. Focus on orthopedic applications, particularly knee osteoarthritis treatments.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Research-grade MSC products |
| Unit Pricing | Pay-as-you-go | Clinical trial supply |
| Other | Pay-as-you-go | Direct-to-consumer clinical treatments |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Cellcolabs product offering
Product offeringCore offering
Cellcolabs is a Swedish biotechnology company that produces GMP-certified mesenchymal stem cells (MSCs) derived from bone marrow at industrial scale in its Stockholm facility under Swedish Medical Products Agency oversight. The company supplies these cells to university hospitals, research institutions, and biotechnology companies for clinical research and therapeutic applications, and also sponsors clinical trials and offers cell therapy access through its Cellcolabs Clinical subsidiary.
Product overview
Cellcolabs is a Swedish biotech company that specializes in large-scale GMP production of mesenchymal stem cells (MSCs). The company's core product is GMP-certified Mesenchymal Stem Cells manufactured in Stockholm under Swedish Medical Products Agency oversight. Cellcolabs operates through subsidiaries including Cellcolabs Clinical for clinical trial sponsorship and Cellcolabs Asia for Southeast Asian commercialization. The company also operates a bone marrow donation program to source cells for production. Their production process, developed over 25 years at the Karolinska Institutet, aims to make high-quality stem cells available at industrial scale with a goal of reducing costs by 90% by 2035.
Differentiator
Problem solved
Functional benefit
Products and services
- GMP Mesenchymal Stem Cells (MSCs) GMP-certified bone-marrow-derived and adipose-derived mesenchymal stem cells cryopreserved at Passage 3 for optimal potency, supplied to university hospitals, research institutions, biotech companies, and clinics for clinical research and therapeutic applications. Each batch is produced under Swedish Medical Products Agency oversight with full traceability.
- Clinical Trial Services (Cellcolabs Clinical) Sponsorship and management of clinical trials assessing MSC therapies for indications including cardiovascular disease, musculoskeletal injuries, Sjögren's Syndrome, and knee osteoarthritis, conducted in markets such as the Bahamas, UAE, Denmark, and Hong Kong.
- Phase 2 Knee Osteoarthritis Study Phase 2 clinical study evaluating MSC therapy for knee osteoarthritis, sponsored through the Cellcolabs Clinical subsidiary and conducted at Burjeel Medical City in Abu Dhabi.
Quantifiable outcome
- 90% cost reduction target for MSC production by 2035
- +3 more outcomes
Companies that use Cellcolabs
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
Cellcolabs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Cellcolabs partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Center for Neuromusculoskeletal Restorative Medicine (CNRM), Chinese University of Hong KongcoreStrategic collaboration under InnoHK initiative supporting Phase I/II clinical trial of MSC therapy for knee osteoarthritis. Cellcolabs contributes GMP-grade MSCs manufactured using protocols from 25+ years of Karolinska Institutet research. MoU signed at Cellcolabs' Stockholm headquarters.
- Rigshospitalet CopenhagencoreCellcolabs supplies GMP-manufactured adipose-derived mesenchymal stem cells (aMSCs) for a Phase I clinical trial at Rigshospitalet, Copenhagen, assessing MSC treatment for xerostomia in Sjögren's Syndrome patients. First clinical use of Cellcolabs' adipose-derived MSCs in Denmark.
- PSL AllianceminorStrategic partnership alliance featured on Cellcolabs' website, indicating collaborative relationship in the regenerative medicine space.
- OA Action AllianceminorPartnership alliance focused on osteoarthritis, aligned with Cellcolabs' priority indication area of knee osteoarthritis treatment.
- Karolinska Institutet / KI Science ParkcoreOrigin of Cellcolabs' stem cell production technology. Company was founded based on pioneering stem cell research of Professor Katarina Le Blanc at Karolinska Institute. Production protocols developed over 25+ years at the institute. Company operates within KI Science Park ecosystem.
Scale indicators6 records
Recent moves5 records
Expansion highlights7 records
Cellcolabs competitors and assessment
Company assessmentDirect peers
- RoosterBio: US-based developer of MSC manufacturing platforms and off-the-shelf MSC products for cell therapy developers. Most directly comparable to Cellcolabs in offering industrial-scale, GMP-grade mesenchymal stem cells to research and clinical customers.
- Mesoblast: Australian-listed commercial-stage MSC therapy company developing remestemcel-L and other allogeneic MSC products for inflammatory and orthopedic indications. Comparable as an MSC-focused biotech pursuing late-stage clinical trials and commercial supply.
- Cynata Therapeutics: Australia-based clinical-stage biotech using a patented platform to manufacture MSC-based therapies at scale from a single donor source. Comparable in focusing on scalable MSC manufacturing and clinical development in orthopedic and inflammatory indications.
- Pluristem Therapeutics: Israel-based cell therapy company developing placenta-derived MSC-like adherent stromal cell products. Comparable as a non-Karolinska MSC platform targeting orthopedic and regenerative medicine indications.
- CellGenix: German-based supplier of GMP-grade raw materials and contract manufacturing services for cell and gene therapy developers. Comparable as a GMP-focused cell therapy manufacturing services provider serving academic and commercial customers globally.
Broad incumbents
- Miltenyi Biotec: Global life-science tools and cell therapy manufacturing company offering MSC products, cell processing instruments, and CDMO services. Comparable as a broader incumbent providing MSC-related products and GMP manufacturing infrastructure across the cell therapy value chain.
- Lonza Group: Swiss multinational CDMO with large-scale cell and gene therapy manufacturing capabilities, including MSC-related services. Comparable as a broad incumbent in cell therapy contract manufacturing with global GMP capacity.
- Catalent (Novo Holdings): Major global CDMO with cell therapy manufacturing services acquired by Novo Holdings in 2024. Comparable as a broad incumbent offering industrial-scale cell therapy development and manufacturing services to biotech customers.
Emerging players
- Atara Biotherapeutics: US-based allogeneic T-cell and MSC-derived therapy developer. Comparable through its focus on off-the-shelf cell therapies and because incoming Cellcolabs CEO Vincent Metzler previously held leadership roles there.
- FUJIFILM Cellular Dynamics: US-based manufacturer of iPSC-derived cells and cell therapy manufacturing services. Comparable as a specialized industrial-scale cell manufacturer serving research and clinical customers, though focused on iPSC rather than bone marrow-derived MSCs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Cellcolabs social profiles
Digital presenceCellcolabs compliance and trust
Trust signalCompliance3 records
Cellcolabs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cellcolabs leadership team
Management profileNumber of profiles
Profiles14 records
Cellcolabs subsidiaries and ownership
Company hierarchySubsidiaries1 record
Cellcolabs funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cellcolabs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cellcolabs
What does Cellcolabs do?
Cellcolabs is a Swedish biotechnology company that produces GMP-certified mesenchymal stem cells (MSCs) derived from bone marrow at industrial scale in its Stockholm facility under Swedish Medical Products Agency oversight. The company supplies these cells to university hospitals, research institutions, and biotechnology companies for clinical research and therapeutic applications, and also sponsors clinical trials and offers cell therapy access through its Cellcolabs Clinical subsidiary.
Is Cellcolabs a public or private company?
Cellcolabs is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cellcolabs founded?
Cellcolabs was founded in 2021. It employs 51 to 100 people.
Where is Cellcolabs based?
Cellcolabs is headquartered in Solna, Sweden, in the Europe region.
How does Cellcolabs make money?
Three revenue lines are on record. Stem Cell Product Sales are the primary driver. The others are clinical Trial Sponsorship and clinical Products and Services.
Who are Cellcolabs's main competitors?
Direct peers on record are RoosterBio, Mesoblast, Cynata Therapeutics, Pluristem Therapeutics and CellGenix. Broad incumbents are Miltenyi Biotec, Lonza Group and Catalent (Novo Holdings). Emerging players are Atara Biotherapeutics and FUJIFILM Cellular Dynamics.
Does Cellcolabs have an API?
No public API is recorded for Cellcolabs.
What industry is Cellcolabs in?
Cellcolabs's product category is Cell Therapy Manufacturing. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic). Its NAICS code is 325414 and its SIC code is 2836.